DOAC (direct oral anticoagulant)

Notification of initiation and transfer of care/prescribing

The DOAC notification of initiation and transfer of care /prescribing agreements for the following are located under policies:

  • Stroke prevention in non-valvular atrial fibrillation
  • Acute treatment or secondary prevention of venous thromboembolism
  • Acute coronary syndrome (rivaroxaban)

Prescribing Guidance

The ‘Anticoagulation selection for stroke prevention in non-valvular atrial fibrillation (NVAF) in adults’ document is currently under review and will be published in due course.

DOAC: Anticoagulation Selection for Stroke Prevention in Non-valvular Atrial Fibrillation (NVAF) in adults

DOAC: Anticoagulation Selection for Stroke Prevention in Non-valvular Atrial Fibrillation (NVAF) in adults visible summary

DOAC: Initiation in Non-Valvular Atrial Fibrillation (NVAF) and monitoring in all indications

DOAC: Rivaroxaban – for Acute Coronary Syndrome

DOAC: Safe Switching of Warfarin to DOAC for Non-Valvular Atrial Fibrillation (NVAF) and Venous Thromboembolism (VTE) – during coronavirus pandemic

DOAC: Calculating renal function

DOAC: Frequently asked questions for primary care